GIC’s Glp-1 Changes & Medicare’s New “Bridge” Program
WHAT MEMBERS NEED TO KNOW
Major changes are coming to GLP-1 medication coverage for both GIC and Medicare members, particularly for medications prescribed for weight loss and obesity management. While some of the GIC changes have already been outlined, details surrounding Medicare’s new “GLP-1 Bridge” demonstration program are still being finalized at the federal level as we went to press.
IMPORTANT NOTE: The information below reflects what we know at press time and remains subject to change as additional guidance is released.
NON-MEDICARE GIC MEMBERS
For non-Medicare GIC members, coverage for GLP-1 medications prescribed solely for obesity will end on June 30, 2026. In addition, the current prescribing arrangement through Vida Health will also end at that time. Beginning July 1, members seeking these medications will need to work directly with their regular health care provider. Prescriptions will require prior authorization through CVS Caremark. The Vida Health program itself is not going away. Members will still be able to access behavioral coaching, weight-management support, and registered dietitian services through Vida — just without the prescribing component.
MEDICARE GIC MEMBERS
Medicare GIC members will have a longer transition period. Current GIC coverage for GLP-1 medications prescribed for obesity will continue through December 31, 2026. After that point, coverage under GIC plans will generally continue only for members who meet CMSapproved clinical criteria. Members seeking additional information about eligibility requirements should consult CMS guidance and materials provided by the GIC. At the same time, Medicare is introducing a new pathway that may provide access to these medications for certain beneficiaries.
Coverage will remain available for:
- Members using GLP-1 medications for diabetes treatment
- Members with a BMI of 27 or higher who also have an FDA-approved comorbidity
MEDICARE PROPOSED “GLP-1 BRIDGE” PROGRAM
In what could become an important development for many retirees, Medicare is expected to launch a temporary demonstration initiative known as the Medicare GLP-1 Bridge Program beginning July 1, 2026. At this point, however, many operational details of the program are still being developed and finalized by Medicare and participating plans. As a result, eligibility requirements, participating medications, costs, and administrative processes could still change before implementation. Based on current information, the program is expected to provide eligible Medicare Part D beneficiaries access to certain weight-loss GLP-1 medications for a flat copay of approximately $50 per month.
At this time, the medications expected to be included are:
- Wegovy (injectable and tablet forms)
- Zepbound (KwikPen only)
- Foundayo
Ozempic is not expected to be included, as the program is focused specifically on weight management rather than diabetes treatment.
POTENTIAL ELIGIBILITY REQUIREMENTS
While final details are still being released, Medicare beneficiaries are expected to need enrollment in a Medicare Part D plan and prior authorization from their physician, demonstrating one of the following:
- A BMI of 35 or higher
- A BMI of 30 or higher with qualifying conditions
- A BMI of 27 or higher with pre-diabetes or certain cardiovascular conditions
Members already taking these medications may be able to qualify using the BMI they had when treatment began, even if they have since lost weight.
WHAT MEMBERS SHOULD DO NOW
Non-Medicare GIC members currently receiving GLP-1 medications through Vida Health should contact their primary care physician or specialist soon to ensure continuity of care before the July 1 transition. Medicare GIC members still have coverage through the end of 2026, but it is a good idea to begin discussing the potential Medicare GLP-1 Bridge Program with your health care provider now to determine whether you may qualify if and when the program moves forward.
We will continue monitoring these developments closely and provide updates as additional information becomes available, provide updates in our weekly emails, hotline messages and our other media outlets.
NEW SPECIALTY DRUG PROGRAM & OUT-OF-NETWORK COVERAGE CHANGES
Two significant changes to Group Insurance Commission (GIC) health benefits will take effect on July 1, 2026, impacting how certain specialty medications are covered and how out-of-network medical services are reimbursed. While many members may not notice any immediate impact, those who take specialty medications or receive care from out-of-network providers should take time to understand the changes and any actions that may be required.
NEW PRUDENTRX SPECIALTY DRUG PROGRAM
The GIC will launch the PrudentRx Specialty Drug Program on July 1, as part of the FY27 plan design changes approved earlier this year.
The program is intended to help reduce out-of-pocket costs for certain high-cost specialty medications by coordinating available manufacturer assistance programs. Members whose medications qualify for the program will generally pay $0 out of pocket for those prescriptions once enrolled.
Importantly, the program does not apply to Medicare-enrolled retirees. Instead, it applies to active employees and retirees who are not yet enrolled in Medicare and who take eligible specialty medications.
According to information provided by the GIC, eligible members will receive communications directly from CVS Caremark and PrudentRx with information about enrollment and next steps. Members who do not enroll in the program may be subject to higher coinsurance costs for medications that are included in the program.
Because members are routinely advised to be cautious when receiving unsolicited calls or requests for personal information, it is worth noting that communications regarding this program are expected to come directly from CVS Caremark, the pharmacy benefit manager for GIC health plans, and PrudentRx. Members who have questions or concerns about any communication they receive should contact CVS Caremark directly at 1-877-876-7214 before providing personal information.
Mass Retirees will continue to monitor the rollout and share additional information as it becomes available.